Shaping the Future of Asthma Management with the NObreath® at ATS 2026

Why It Matters

FeNO testing enables precise asthma phenotyping, leading to tailored therapies and reduced exacerbations, positioning NObreath® as a strategic tool for clinicians and health systems seeking cost‑effective respiratory care.

Key Takeaways

• NObreath® displayed at ATS 2026 booth 1236.
• FeNO device offers non‑invasive airway inflammation measurement.
• 15+ years of clinical use improves asthma care globally.
• Bedfont partners with U.S. distributor coVita™ for market expansion.
• Carol Stonham to present FeNO insights on May 17.

Pulse Analysis

The ATS International Conference remains the premier gathering for respiratory professionals, offering a platform where emerging diagnostics can gain rapid visibility. In this environment, Bedfont’s NObreath® stands out by delivering point‑of‑care FeNO measurements that align with the growing emphasis on personalized medicine. Clinicians increasingly rely on objective biomarkers to differentiate eosinophilic from non‑eosinophilic asthma, and the ability to quantify fractional exhaled nitric oxide in minutes supports more accurate treatment selection and monitoring.

Beyond clinical utility, the NObreath® reflects broader MedTech trends toward non‑invasive, patient‑centric solutions. As healthcare systems grapple with rising asthma prevalence and the cost of uncontrolled disease, devices that reduce the need for invasive procedures or extensive lab work are gaining traction. Bedfont’s half‑century of expertise in breath analysis, combined with coVita™’s U.S. distribution network, positions the company to capture market share in both hospital and outpatient settings, where rapid, reliable data can streamline care pathways and improve reimbursement outcomes.

The inclusion of Carol Stonham, MBE, as a speaker underscores the device’s credibility among key opinion leaders. Her discussion on FeNO’s role in pediatric and adolescent asthma care highlights an expanding niche where early intervention can alter disease trajectory. As insurers and policymakers prioritize value‑based care, technologies like NObreath® that demonstrate measurable reductions in exacerbations and steroid use are likely to see increased adoption, reinforcing Bedfont’s strategic foothold in the evolving respiratory diagnostics landscape.